Michael Krathen is a Dermatology physician affiliated with Boston Medical Center. OpenAlex indexes 23 publications with 771 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
220 N Main St Ste 201
Natick, MA 017601100
Telephone
508-545-9713Provider last certified this registry record 1 Jan 2026.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- ABBVIE INC.Program year20253 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
27.9%Corticosteroid14.3%Triamcinolone Acetonide81%Triamcinolone acetonide19%Part D + Part B≥74 patientsInterleukin-4 Receptor alpha Antagonist4%Dupixent Pen100%Part D<11 patients+ 5 more classes in this area
Cardiovascular
14.3%Arteriolar Vasodilator11.6%Minoxidil100%Part D≥30 patientsAldosterone antagonist (MRA)1.4%Spironolactone100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
13.3%5-alpha Reductase Inhibitor13.3%Finasteride100%Part D≥42 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cutaneous Rosai–Dorfman Disease With Linear Lesions and Monoclonal Gammopathy
American Journal of Dermatopathology
2017 - Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial
Journal of the American Academy of Dermatology
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Alice Jacobs, MD
Boston Medical Center
Carlos Kase, MD
Boston Medical Center
Sushrut Waikar, MD
Boston Medical Center
Geoffrey Oxnard, MD
Boston Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”